Skip to content
2000
Volume 1, Issue 3
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

N-Oxide-containing compounds have been developed as prodrugs that are selectively bioactivated in the hypoxic cells in tumors. This selectivity is based on the net reduction of the N-oxide moiety in the absence of oxygen, in a one or two-electron process, by reductive enzymes. A wide range of N-oxides have been studied and some of them are currently in clinical use. This review covers the principal families of compounds under study and in clinical trials.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557013406891
2001-09-01
2025-10-20
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557013406891
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test